{"preliminary_commentary":{"by_channel":{"x_thread":10},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06183489\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["elranatamab"]],"indication":"high-risk smoldering multiple myeloma","name":"ERASMM","nct_id":"NCT06183489","offer":{"currency":"USD","how":"Buy the first edition with create_order on https://mcp.erudio.com/mcp (product \"first_edition\", report \"NCT06183489\", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/erasmm-nct06183489. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"product":"first_edition","size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ERASMM","arms":[{"description":"Participant will receive elranatamab subcutaneously (SC) for 24 cycles (28-day cycle)","label":"Elranatamab","type":"EXPERIMENTAL"}],"collaborators":["Pfizer","EMN Trial Office S.r.l. Impresa Sociale"],"completion_date":{"date":"2031-07","type":"ESTIMATED"},"conditions":["Smoldering Multiple Myeloma"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elranatamab","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-02","lead_sponsor":"European Myeloma Network B.V.","official_title":"A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Complete Remission (CR) rate","timeFrame":"average 24 weeks"}],"references":[],"start_date":{"date":"2024-05-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06183489"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/erasmm-nct06183489"}